In contrast, the number of those dispensed drugs other than GLP-1 receptor agonists fell from 12,683,040 to 12,282,525, for a decrease of 3.1%
GLP-1s enhance blood sugar control and other metabolic markers by stimulating the release of insulin, a hormone that regulates blood sugar, while suppressing the secretion of glucagon, a hormone that raises blood sugar
The SURPASS trials showed triglyceride reductions of 19-25%, which is comparable to what some dedicated lipid-lowering medications achieve
The views expressed in this article are the views of the expert and do not necessarily represent the views of Healf Pippa is a content writer and qualified Nutritional Therapist (DipNT) creating research-based content with a passion for many areas of wellbeing, including hormonal health, mental health and digestive health
Theres no clinical basis to choose between starting low and staying low versus titrating up